title: Comparative in vitro activities of SMT19969, a new antimicrobial agent, against 162 strains from 35 less frequently recovered intestinal Clostridium species: implications for Clostridium difficile recurrence.
abstract: We determined the comparative activity of SMT19969 (SMT) against 162 strains representing 35 well-characterized Clostridium species in clusters I to XIX and 13 Clostridium species that had no 16S rRNA match. SMT MICs ranged from 0.06 to >512 μg/ml and were not species related. SMT might have less impact on normal gut microbiota than other Clostridium difficile infection (CDI) antimicrobials.
authors.affiliation: R. M. Alden Research Laboratory, Culver City, California, USA.
authors.forename: Ellie J C
authors.initials: EJ
authors.lastname: Goldstein
authors.forename: Diane M
authors.initials: DM
authors.lastname: Citron
authors.forename: Kerin L
authors.initials: KL
authors.lastname: Tyrrell
mesh_terms: D000617:Aminoglycosides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016360:Clostridioides difficile / Q000187:drug effects / Q000235:genetics; D003013:Clostridium / Q000145:classification / Q000187:drug effects* / Q000235:genetics; D016000:Cluster Analysis; D000077732:Fidaxomicin; D008795:Metronidazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D012336:RNA, Ribosomal, 16S / Q000145:classification / Q000235:genetics*; D013045:Species Specificity; D014640:Vancomycin / Q000494:pharmacology
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D012336:RNA, Ribosomal, 16S; D008795:Metronidazole; D014640:Vancomycin; D000077732:Fidaxomicin